Lisinopril use during pregnancy
Pro Research Analysisby 
Searched over 200M research papers
Lisinopril and Pregnancy: Safety Concerns and Risks
ACE Inhibitors and Fetal Development
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is commonly used to treat hypertension. However, its use during pregnancy is associated with significant risks to the fetus, especially beyond the first trimester. Studies and case reports have shown that exposure to lisinopril during pregnancy can lead to fetal malformations, neonatal complications, and even perinatal mortality, particularly when used after the first trimester 1256.
First Trimester Exposure: Limited Evidence of Harm
Some evidence suggests that lisinopril use limited to the first trimester may not always result in adverse fetal outcomes. For example, a case where lisinopril was discontinued at 8 weeks gestation and replaced with methyldopa resulted in a healthy baby with no detected abnormalities . However, animal studies indicate that lisinopril can be teratogenic, causing developmental issues such as stunted growth and craniofacial malformations in mice, even with early exposure .
Second and Third Trimester Exposure: High Risk of Complications
The risks associated with lisinopril use increase significantly in the second and third trimesters. Documented complications include fetal renal failure, oligohydramnios (low amniotic fluid), and other organ dysfunctions. Neonates exposed to lisinopril in utero have developed severe renal failure, sometimes requiring early peritoneal dialysis or other interventions. While some infants have survived with intensive treatment, others have experienced long-term renal impairment or death 126.
Management of Neonatal Complications
When neonatal renal failure occurs due to lisinopril exposure, early dialysis is recommended to help remove the drug and support recovery. Peritoneal dialysis has been used with some success, but its effectiveness in clearing lisinopril is limited, and alternative methods like hemodialysis may be more effective if available 26. Despite aggressive management, outcomes can still be poor, and long-term complications are possible 26.
Counseling and Clinical Recommendations
Current clinical guidance strongly advises against the use of lisinopril and other ACE inhibitors during pregnancy, especially after the first trimester. In rare, severe cases where other antihypertensive medications are ineffective, lisinopril may be considered, but only with full counseling of the patient regarding the potential risks to the fetus and the likelihood of neonatal complications .
Animal Studies and Additional Risks
Animal studies reinforce the teratogenic potential of lisinopril, showing significant developmental delays and malformations in offspring exposed during gestation 58. These findings support the caution exercised in human pregnancies.
Conclusion
Lisinopril use during pregnancy, particularly after the first trimester, poses significant risks to fetal and neonatal health, including renal failure, developmental abnormalities, and increased mortality. While first trimester exposure may sometimes result in normal outcomes, the overall evidence supports avoiding lisinopril throughout pregnancy whenever possible. Alternative antihypertensive therapies should be prioritized, and patients should be thoroughly counseled about the risks if lisinopril use is considered unavoidable.
Sources and full results
Most relevant research papers on this topic